Illumina, Inc. (ILMN) Earnings Call Transcript & Summary

February 5, 2026

NASDAQ US Health Care Life Sciences Tools and Services earnings 59 min

Earnings Call Speaker Segments

Conor McNamara

executive
#1

Good day, everyone, and thanks for joining us for Illumina's call covering the fourth quarter of 2025. During this session, we'll go over the financial results we published following the close of the market, share some prepared comments, and then take your questions. You can find our earnings release in the Investors Relations area of illumina.com. With us today are Jacob Thaysen, our Chief Executive Officer, and Ankur Dhingra, our Chief Financial Officer. Jacob will begin by giving an update on Illumina's business, and after that Ankur will walk through the company's financials. Certain non-GAAP financial measures will be covered on this call, and a reconciliation to GAAP appears in today's release as well as in the supplementary data posted on our website. Please keep in mind that, unless stated otherwise, or when we're referring to end markets, every year-over-year revenue growth rate mentioned in our prepared remarks is given on a constant currency basis, leaving out the effect of foreign exchange fluctuations; also, whenever we mention China, we mean our Greater China region, which takes in Taiwan and Hong Kong as well. This call is being recorded, and a replay will be made available in the Investor section of our website; we intend for all forward-looking statements made during today's call to be protected under the Private Securities Litigation Reform Act of 1995. To gain a better understanding of the risks and uncertainties that might cause actual results to differ, please see the documents Illumina files with the SEC, among them our most recent forms 10-Q and 10-K. With that, I'll hand the call over to Jacob. Thank you, Conor.

Jacob Thaysen

executive
#2

Good afternoon, everyone. I’m happy to share that our fourth-quarter results came in above what was expected, finishing with a 20% increase in clinical consumables revenue ex-China, which shows execution across the organization as we wrapped up 2025. We made enormous strides during the year, and the momentum built as we head into 2026 gives me strong confidence that the strategy introduced in 2024 to get back to long-term growth is delivering. Among our 2025 achievements: we returned to growth in 2025, with ex-China revenue up 2% for the year and up 7% in Q4. Clinical consumables revenue growth sped up across the year, with mid-teens growth in the second half and Q4 growth of 20% ex-China. We reached the high throughput transition milestones we had set out to reach. We moved our portfolio past core sequencing into multiomics and data software and AI, and we increased non-GAAP operating margins by 180 basis points and lifted non-GAAP EPS by 16% year over year. We produced robust free cash flow and gave back roughly $740 million to shareholders via share repurchases. All of that happened in a fast-changing market, and our team members remained ahead of many dynamic developments seen during the year. Our 2025 success demonstrates the strength of the Illumina team, and I want to acknowledge their continued dedication to our customers through innovation and execution. Now I want to go deeper on the success we are seeing in our clinical business, where revenue growth accelerated throughout 2025. The strength in clinical consumables, including 20% ex-China growth in Q4, is mainly being driven by two factors. First, uptake of sequencing-based diagnostic tests keeps rising as customers launch new assays and broaden reimbursement coverage in areas such as minimal residual disease and early cancer detection testing. Second, we see wider demand for comprehensive genomic profiling and whole genome approaches in oncology and genetic diseases, both of which call for greater sequencing intensity and gain from the power and consistency of the NovaSeq X. As customers scale more data-intensive applications on a more powerful platform, the elasticity dynamics discussed in prior quarters continue to take hold; this is producing strong instrument sales. Q4 was the second highest quarter placement since the NovaSeq X launched in 2023, while also speeding consumables demand that supports durable growth in our core sequencing business. Next-generation sequencing remains vastly underutilized, and we are positioning our business to capture growth as the market evolves. One illustration of this is the recent addition of Dr. Eric Green as our Chief Medical Officer. Eric brings deep experience in genomics and healthcare policy, most recently serving as director of the National Human Genome Research Institute at the NIH. His leadership in the field will be a catalyst for driving continued adoption of genomics and multiomics toward standard of care for patients. I now want to discuss how our long-term strategy is working. Back in 2024, we laid out three pillars for strategic growth: core sequencing, scaling multiomics, and broadening what we offer in services, data, and software. Sticking with those pillars produced solid results in 2025, and that puts us in a good spot for 2026 and afterward. Let me take you through some illustrations of how we've advanced on each pillar. Pillar one is core sequencing, with the NovaSeq X at its center. As noted before, clinical is still our biggest growth engine, and rising test volumes featuring applications that lean heavily on sequencing strengthen the need for high throughput, top-quality sequencing on the NovaSeq X; on the research side, conditions remain measured. Buyers are still careful when making purchase calls, even though we're noticing indications of stabilization, among them clearer visibility on US policy and the funding landscape. Over a longer horizon, we think our research business can get back to healthy growth, yet at this point we're modeling end market dynamics in '26 that resemble what we experienced in 2025. Pillar two is scaling into Multiomics, where we're assembling a broad portfolio of integrated solutions that stretch the Illumina sequencing ecosystem. That covers capabilities we develop in-house as well as targeted acquisitions where we identify technologies capable of meaningfully widening our long-term growth opportunity. One illustration: we just finished acquiring Somalogic, a key milestone that extends our long-standing partnership. I'd like to officially welcome the Somalogic team to Illumina; we're thrilled about what we'll create together as we bring our combined capabilities further together. Somalogic's Aptima-based affinity proteomics platform lets researchers produce substantial insight with high sensitivity, high throughput, and thousands of protein markers in one experiment. Our merged proteomics offerings will deliver deep insight into protein function, interactions, and modifications at scale, which helps speed up understanding of complex biology and human health. Proteomics sits at the frontline of multiomics, and now that Somalogic is part of Illumina, our standing in this key growth market is much stronger. By bringing the scale of NGS to proteomics, we can speed innovation by cutting the time and cost of protein analysis. Across genomics, proteomics, single-cell, and epigenomics, these capabilities are now being united through Illumina Connected Multiomics, which we recently launched; this software tackles a challenge that has long persisted in the field: integrating and interpreting data across differing data types by simplifying multiomics analysis and making workflows more scalable and simpler for customers to use. Going forward, we remain on track to roll out our spatial transcriptomics solution in 2026 together with our Constellation MAP Read technology during that same period. Combined, these advances broaden our ability to provide integrated end-to-end workflows that support customers as multiomics pushes further into research and clinical settings alike. Pillar three is expanding our services, data, and software capabilities. During Q4, we rolled out BioInsight — a major move toward broadening the ways Illumina backs discovery and drug development via data, software, and AI. Four critical enabling pieces are coming together for the very first time: sequencing at scale, tools that perturb biology with CRISPR across genome-wide levels, dedicated compute capacity for analyzing it, and AI for constructing predictive biological models. By uniting our top-tier strengths across those four domains, BioInsight is set to radically transform drug discovery. Rather than depending on years of iterative wet lab work, pharmaceutical and biotech firms can more and more build, test, and refine biological models in a digital environment — speeding up timelines and boosting success rates. Last month brought the debut of BioInsight's first data product: the Billion Cell Atlas, destined to become the most comprehensive map of human biology for drug discovery. Created through single-cell methods, CRISPR-based perturbation, and AI, the Atlas lets partners grasp disease mechanisms better and sharpen target validations. Strong interest from biopharma partners greeted this Billion Cell Atlas, and we unveiled initial collaborations with AstraZeneca, Merck, and Eli Lilly. Engagement keeps growing among additional partners as data-driven approaches pick up momentum in drug discovery. All told, BioInsight widens how customers produce and respond to biological insight while reinforcing Illumina's standing in biopharma — a growing portion of our research end markets. Later this month at AGBT, our customers get their next chance to witness how our strategy and innovation fit together.

Jacob Thaysen

executive
#3

Serving as the gold sponsor for this year, we'll be accompanied by customers along with key opinion leaders, and they'll discuss the ways our latest platform improvements plus genomic and multiomics assays get used in actual research and clinical environments. One central theme we intend to highlight is how much our customers gain from our fully integrated, start-to-finish solutions. What customers tell us in conversation has moved away from cost per gigabase toward the overall expense of the workflow — everything from preparing samples all the way through analysis and interpretation — since integrated workflows and data quality are what count most there. This strategy, which means we keep innovating as the market shifts, gives customers confidence in the durable, long-term worth of our flagship sequencing instruments, while also helping them where the field is going, such as deeper uptake of genomic and multiomics approaches; now let's discuss what we expect for 2026. Carrying forward the momentum from 2025, our projection is organic revenue growth between 2% and 4% for 2026, not counting China, with demand overall comparable to 2025 levels. Clinical consumables rose about 16% outside China during the second half, and we anticipate that strong growth will persist through 2026. Our forecast presumes clinical growth in the double-digit to mid-teens range during 2026; we see no basic shift in academic end markets for 2026, which leads to mid to high single-digit declines in revenue from our research and applied consumables. For instruments, we anticipate roughly flat to slightly lower results, bringing total company revenue to between $4.5 and $4.6 billion, which equals reported growth of 4% to 6%. We project operating margins of 23.3% to 23.5% for 2026, roughly 130 basis points higher when you exclude the acquisition impact. EPS guidance sits at $5.00 to $5.20, and that includes $0.18 of dilution tied to the Somalogic acquisition. Without that dilution, it amounts to 10% growth year over year. Before Ankur walks us through the specifics of Q4 and what we're expecting in 2026, let me just say this: I have confidence that the strategy we've built for the long haul is delivering, and the evidence is in what we accomplished during 2025 and in the position Illumina occupies right now. Over the last twelve months, we advanced the plan we laid out back in 2024, made solid strides across every part of the business, and we're carrying real momentum into 2026. We showed we can weather challenges, we've come out stronger, and our path toward the long-term financial goals we've set for 2027 remains intact. My thanks go out to everyone at the company for how hard they worked and what they delivered this year. I want to say how much admiration I have for everyone at Illumina—they kept their eyes on the mission throughout a year full of change, and they came through for the people who buy from us as well as the patients those customers look after. At this point, I'll hand things over to Ankur so he can take us through the numbers, and after that we'll open it up for questions. Thanks, Jacob, and good afternoon to all of you.

Ankur Dhingra

executive
#4

Let me take you through the financial picture for the fourth quarter — I'll add some color on revenue, expenses, and earnings, share where the balance sheet stands and how we're putting capital to work, and then cover our outlook going forward. But before I get into the financial details, I'd like to give you a broader view of how Q4 played out. Illumina posted fourth quarter revenue of $1.16 billion, coming in ahead of our expectations, driven by strength in clinical consumables revenue, NovaSeq X placements that came in above our forecast, and better-than-expected results in China; we also saw a modest lift from year-end budget purchasing. Since we brought in more revenue, both our margins and EPS came in above what we had guided, and those results also showed the gains from the cost-cutting steps we implemented earlier this year. Let me now walk you through the specifics. For the fourth quarter, Illumina posted revenue of $1.16 billion, which was up 5% from a year earlier as reported and 4% in constant currency terms. Revenue from Greater China reached $55 million, beating what we had expected, though that figure was down $25 million compared with 2024. When you take Greater China out of the picture, Illumina's revenue grew 7% year over year. Sequencing consumables brought in $755 million, an 8% year-over-year increase, or 11% once China is excluded. On this call, we saw consumables perform well because of large increases in throughput volume, with customers in both research and clinical settings increasing how much they used their NovaSeq X machines. Beyond that, the clinical sector kept up its positive trajectory, posting 20% growth when China is excluded. This came from wider uptake of NGS-based testing, plus labs switching existing assays over to versions needing far more sequencing data — for example, moving from whole exome to whole genome sequencing in oncology and genetic disease. During the quarter, consumable revenue across research and applied markets was approximately level compared with the same period last year, which marks a clear step up from Q3, though it remains under where it has historically been, as funding conditions stay uncertain. Conversion to the X accounted for about 80% of the volumes and the year-over-year pricing patterns. During the fourth quarter, 55% of our revenue has already moved over to NovaSeq X. On the research side, that shift is almost finished — about 90% of those customers' high throughput sequencing volumes have now moved to 2026. For clinical, more than two-thirds of the volume has converted to the X, and our view is that future pricing will depend more on new applications, such as whole genome sequencing adoption, which pushes volumes higher. With those two factors in play — research nearly fully converted and clinical volume growing because of the X — we anticipate that the transition will be largely done by 2026. Regarding sequencing activity: output measured in gigabases across our linked high- and mid-throughput platforms rose over 30% compared with the prior year, with clinical demand quite strong while research customers showed softer growth. Revenue from sequencing instruments reached $154 million, roughly level with a year earlier in Q4 and 3% higher excluding China, helped by solid placements of NovaSeq X and the 100. As with consumables, clinical buyers represented over 60% of X systems placed in Q4. In Greater China, our instruments business declined 55% owing to export restrictions. Globally, we ended up placing over 100 NovaSeq X units, and about five of those came through rental or lease arrangements, taking our active installed base up to 890 instruments. Revenue from sequencing services and other sources was $157 million, which is an increase of roughly 3% compared with the same period last year, or 4% if you take China out of the picture. Data deals and strategic partnerships have followed an uneven pattern throughout 2025, so it was encouraging to get back to growth in Q4. Now looking at the other P&L lines, non-GAAP gross margin for Q4 landed at 67%, down 40 basis points year over year, with tariffs accounting for 205 basis points of that decline. Excluding the impact of tariffs, gross margins improved by 165 basis points compared with the prior quarter. As for the fourth-quarter margin profile, it follows our typical tendency for a period in which instruments carry a heavier weight on the non-GAAP operating expense line. We recorded $502 million in operating expenses, down 5% year over year, or $24 million, which illustrates the payoff from our multiyear cost reduction efforts and the way we have prioritized investments in key growth areas. For Q4, non-GAAP operating margin came in at 23.7%, up 400 basis points from the same period a year ago. Operating profit was up about 26% versus the prior-year period, reflecting stronger operating leverage produced by our improved cost structure. Now looking below the line, non-GAAP other expense, mostly made up of net interest expense, came to $16 million, while the non-GAAP tax rate stood at 19.5%. We keep evaluating long-term optimization of our tax structure so that US R&D benefits are balanced against efficient credit utilization in various jurisdictions. Average diluted shares were about 154 million, which is 6 million below '24, a result of share repurchases made over the course of the year. Taking everything together, non-GAAP EPS was $1.35 per diluted share, an increase of roughly 42% from a year ago, finishing above our guidance range and exceeding the initial estimate we shared in January. Turning now to the quarter's cash flow, balance sheet, and how we're allocating capital. Operating cash flow for the quarter was $321 million, and for the full year it reached $1.1 billion. Our capital expenditures totaled $54 million, which put Q4 free cash flow at $267 million; over the year, CapEx was $148 million and free cash flow amounted to $931 million. In Q4 we repurchased 337,000 Illumina shares for roughly $42 million, paying an average of $124.12 per share. At quarter end, $643 million remained available under our repurchase authorization, and we intend to continue buying back stock as opportunities present themselves. Once the fourth quarter wrapped up, the Somalogic deal closed on January 30. We paid $350 million upfront, and there could also be royalties and milestone payments, depending on the usual adjustments. The upfront amount came out of cash we already had. When the quarter closed, we held about $1.63 billion across cash, cash equivalents, and short-term investments, and gross leverage stood near 1.6 times, measuring gross debt against last twelve months EBITDA. Now, for a look back at 2025 in full, let's start with revenue. Outside China, growth returned in Q3, and over the back half of the year, sales rose by about 4%. I feel tremendous pride in the entire Illumina team for steering through a year that was highly dynamic and finishing it strongly. Thanks to disciplined execution and cost optimization, we managed to widen margins by close to 200 basis points during 2025, even with macro-related headwinds of about 200 basis points. And last, EPS rose 16%, and at $4.84, our 2025 EPS landed above the initial guidance provided at the beginning of the year. The manner in which we finished 2025 leaves me confident regarding the progress we're making toward our long-range targets, and our momentum as we head into 2026 has me excited; let me now turn to guidance for 2026. Starting off with the top line, we're looking at somewhere between $4.5 billion and $4.6 billion. That works out to organic growth of 2% to 4% when you strip out China. When we talk about organic, we're setting aside currency effects, and those should add roughly one point to what we report. On top of that, there's revenue from the Somalogic acquisition, which ought to bring in another 1.5 to two points of growth during 2026. Meanwhile, our sales in China are expected to drag down total company revenue growth by one point. So when you put it all together on a reported basis, total revenue should be up 4% to 6%.

Ankur Dhingra

executive
#5

For the remaining global markets, looking at organic sequencing revenue growth, we're anticipating low to mid-single-digit expansion in consumables, whereas clinical is expected to increase double-digit to mid-teens, fueled by sustained robust volumes from our clinical customer base. We're enthusiastic about the considerable strides our customers are achieving through growth in their on-market tests and new sequencing-intensive whole genome approaches. Research, we anticipate, will drop mid to high single digits. The recent NIH budget announcements represent a positive step, and if funding flow picks back up, that could create a better landscape compared to what our guidance currently assumes. For our instruments, we expect a year-over-year result ranging from a slight single-digit decline to no change at all, and we anticipate that our target of averaging 50 to 60 NovaSeq X placements each quarter will hold steady through 2026. Details on the pull-through assumptions for each platform are available in our earnings presentation. Regarding China, our outlook is for $210 to $220 million in sales, with instrument sales showing little to no sequential improvement during the first half; as we engage with the government on our capacity to bring instruments into that country, we will reassess our assumptions. Turning to operating margins, if we set Somalogic aside, our guidance calls for a 130 basis point expansion at the midpoint next year. For margins, Somalogic should create a drag of 100 basis points. Looking at the full year 2026, our operating margin projection sits between 23.3% and 23.5%. Our work to lift Illumina's operating margins has advanced considerably, and we're staying committed to hitting the targets we set for 2027. Turning to EPS: if you set Somalogic aside, we anticipate 10% growth at the midpoint. At the midpoint, Somalogic is anticipated to dilute results by $0.18. So for Illumina overall in 2026, EPS guidance lands between $5.00 and $5.20. In Q1 2026, organic revenue growth for the rest of world should come in at 1% to 3%, which works out to $1.06 billion to $1.08 billion. Q1 EPS should be $1.02 to $1.07, and that figure includes $0.04 of dilution. You can find the remaining specifics about our Q1 results and our 2026 guidance in the earnings presentation. One quick administrative note: as of January 2026, we reorganized our geographical reporting segments so they line up more closely with how each commercial organization is structured. So when Q1 comes around, we'll start reporting under those new geographical segments, and we'll also supply a historical financial reconciliation reflecting the new structure. To wrap up, I'd like to say thank you once more, and sincerely, to everyone at Illumina for staying focused and executing with discipline all quarter long. We're heading into 2026 carrying considerable momentum, and the strides we've taken toward getting Illumina back to sustainable revenue and earnings growth over the long term give me a great deal of encouragement. Thanks for being with us on today's call. At this point, I'll ask the operator to open up the phone lines so we can take your questions.

Doug Schenkel

analyst
#6

Hi there. Good afternoon, everyone. I'll begin with a few questions about the financials, then rejoin the queue afterward. Starting with operating margin: does the guidance include an assumption that you basically finish the year with an operating margin between 26% and 27%? And following from that, has anything changed regarding your 2027 margin target now that Somalogic is factored in? The second subject is really capital deployment. At this point the balance sheet is quite clean. You're producing roughly a billion dollars in free cash flow. The business has clearly stabilized. What's your thinking on capital deployment? And more specifically, what are your M&A criteria and priorities? Thank you.

Jacob Thaysen

executive
#7

Thank you, Doug. Let me begin by taking your first question, which I think concerns our long-term targets. We continue to feel very good about those targets. To step back for a moment, in '24, we presented that we would return the business to high single-digit growth by '27 while also delivering 500 basis points, bringing us to a 26% operating margin. We feel really good about what we've accomplished over the last year; we've moved ourselves into growth, and we believe we're headed in the right direction to achieve high single-digit growth in '27 within our core business; we're also seeing that we've advanced considerably on our operating margins, with 200 basis points last year in what was truly a difficult environment, where we faced roughly 200 basis points of headwinds from tariffs and other items. And now we're committing to an additional 130 basis points; so we're well along that trajectory. Of course, with the Somalogic acquisition now, it will be, as we also said, dilutive at the outset. We're working through the synergy opportunities, and we'll get as close to the 26% operating margin as we can in '27 as well; but beyond that, we'll keep you updated along the way. We're doing everything we can.

Ankur Dhingra

executive
#8

Okay, this is Ankur speaking. Doug, your assumption that, once you take Somalogic out of the picture, the operating margin we exit 2026 at comes in above the average — that pattern reflects the usual cyclicality we see in this business. For the full year, our guidance stands at 24.5%, and the rate we exit at in Q4 typically runs above that figure.

Vijay Kumar

analyst
#9

Hey, everyone. I appreciate you taking my question, and congratulations on a solid finish. Perhaps one about the guidance. Jacob, or Ankur, this is for you. Regarding the organic figure for Q4, looking at clinical performance, it was 6.5% ex-China, and 3.5% for the whole company. For fiscal '26, on an ex-China basis, your guidance points to 3%; so what's behind that decline from the 6.5% exit rate we saw in Q4? When you look at Q4, clinical was clearly standard. Did anything one-off happen in Q4? Was there any revenue pull forward, or anything like that, which might justify some tempering in the '26 outlook? Thank you.

Jacob Thaysen

executive
#10

Hey, Vijay. Thank you. Above all, we're really thrilled with the way we closed out the year. Obviously, 2025 was a tough year. So the momentum we began to establish in the second half is quite encouraging; and we genuinely think that momentum carries forward into '26. As you saw, we finished the year with really strong clinical performance, with 20% growth in clinical consumables during Q4 of '25. And we anticipate that overall momentum from the second half will persist. So we think what we've baked in is high mid-teens growth for our clinical business. Yet we also keep seeing the channeling within the research academic setting. It's certainly a positive step that we now have a line of sight to the NIH budget. But looking a bit more closely, plenty of uncertainty remains for the institute regarding how grants get distributed and who actually receives those grants. So that's our observation. The environment is still muted, and I think over the course of the year we'll hopefully see that improve, which could sustain or even boost our performance. But we aren't seeing any meaningful step down. We recognize Q4 is consistently a strong quarter, and so we feel confident about how we're guiding right now.

Ankur Dhingra

executive
#11

Vijay, when it comes to the guidance, let me put the 2% to 4% China figure in context. Like Jacob mentioned, momentum hasn't shifted at all, particularly in the clinical business. Our customers keep performing very well, whether through uptake of the on-market test or through efforts to launch new tests. Our approach to the guidance was to examine the half of 2025 the way it unfolded during the Q3 earnings call. During Q3, growth came in at 2% ex-China. It climbed to 7% in Q4; therefore we averaged the second half to set the range for our overall guidance. We're treating 2025 as the low end. Right, with clinical still expanding at a double-digit rate. Research was tapering off at a high single-digit rate. That's roughly the framework for the low end. And should research pick up, that clearly offers upside. Using Q4, just one quarter, didn't seem right as a base for a full-year guide as such. But momentum is momentum.

Puneet Souda

analyst
#12

Yes. Hello, everyone. I appreciate you taking the question. Regarding instrumentation, could you break down how it divided between research and clinical? The momentum on the clinical side is something I appreciate, but when it comes to research, could you give us some background and also share your thinking on the broader competitive landscape, beyond the academic pressure we've observed in the market? How much of that is already reflected on the research side, at both the mid throughput and high throughput ends?

Jacob Thaysen

executive
#13

Yes, Puneet. Thank you. We're quite happy with how we performed in Q4, with over 100 instruments placed on the X instruments. As anticipated, over 60% of those placements were tied to clinical. We expect that to remain true, with that dynamic carrying into '26, when clinical will account for the majority of instrument placements. So we keep seeing customers build their assays on the X instruments, and we aren't observing any slowdown in that portion of the business. As you also pointed out, we have a mid throughput business; that one has been more, as we discussed previously, more challenged by certain macro trends, where some of our customers may have been more conservative in how they spent their funding in recent years, including in the research and academic market; so I believe that market remains somewhat more muted, though not really a shift from what we saw in '25. That's how we view the business at this point.

Ankur Dhingra

executive
#14

When we look at it through a competitive lens, Puneet, the answer is no — Q4 didn't bring much of that. Like Jacob mentioned, it was a really robust quarter for instrument placements overall, spanning both clinical and research. The interest we're seeing in the new launches is quite encouraging. We've brought out the five base. Spatial is currently in early access, and on the research side, both demand and interest appear very promising. As far as how we're thinking about research looking toward 2026, it hinges more on the funding environment and how that environment itself evolves.

Tycho Peterson

analyst
#15

Hey, thanks, guys. A few quick ones. First, on the clinical side, Jacob, you mentioned increased adoption of whole genome and whole exome. Could you break down how much of that growth is mix versus perhaps volume? That's the first question. Second, regarding Onso, I'm curious if you could address that. And your thinking on how soon you could bring that technology in, if that's something you intend to do. Then, lastly, on adjacencies, a bit more detail on what you're assuming for spatial constellation and five base.

Jacob Thaysen

executive
#16

Okay, so no. Thanks for that, Tycho. If you consider the opportunity with the X and what our customers use it for, clearly, we keep seeing — as you can tell, a lot of our clinical customers are obviously experiencing substantial volume growth. More physicians are beginning to rely on genetic profiling for cancers, and for tracking disease as well. So that's strong momentum. But we also observe our customers opting for bigger and bigger panels. As you said, certain ones are moving from exome to whole genome. That's more within the genetic area; yet we're also seeing customers construct larger panels for therapy selection. And what comes next is broadening the panels for MRD. So we see all of that. We aren't breaking it down into the components right now, but I'd say as time goes on, I think, in fact, the intensity — meaning the larger panels — will be the primary growth driver moving forward. We see plenty of opportunities there. Regarding the acquisition of the IP from PacBio, we viewed that as a terrific chance to bolster our portfolio; we're quite bullish on our SPS technology, so we think there remain many options there. But we felt it was an excellent way to preserve optionality. And then I believe the last thing you had was about how much we've factored in for the five base. And for Constellation and others. It's still early days. We've seen extremely strong interest for the products we've already brought to market. I don't think it will be meaningful in '26, really, but it will begin to be meaningful, as we discussed previously, in '27 and beyond, where we believe one or two basis of growth — one or two percent growth — will come from our new assays in multiomics, both multiomics and our data, the BioInsight business.

Michael Ryskin

analyst
#17

Thanks a lot for fielding my question, folks. I'd like to dig into a few of the components of 2020 regarding sequencing consumables and sequencing instruments. Honestly, it caught me a bit off guard that the two came in so near each other. My assumption had been that sequencing plus consumables would have performed somewhat stronger, given that, as you put it, you're getting beyond certain obstacles caused by the price transition. Conversely, on sequencing instruments, my sense was things might have turned out somewhat weaker. So if you wouldn't mind unpacking a few of those shifting elements, are you anticipating a comparable situation for NovaX placements in the coming year, somewhere in the mid to high 200s? And perhaps you could also address the other platforms that contribute to that total, like the NextSeq, the mid throughput platforms, and the NovaSeq 6K. We'd really appreciate additional detail on those moving parts. Thanks.

Jacob Thaysen

executive
#18

Hi, Mike. Thanks for raising those questions. Let me say that, above all, when it comes to high throughput consumables, particularly within clinical, as we noted, we keep witnessing extremely robust results there; therefore we don't anticipate any shift on that front. In fact, we believe there could be potential upside there, clearly, should the market stay as robust as what we witnessed during the later portion of the year. Naturally, within consumables, when you combine the ones for the research segment along with those for mid throughput, some obstacles remain in that area. That explains why the blended figure lands where it does. Here's how I'd frame it. Consider that the bottom end of our guidance for consumables likely reflects what Q3 looked like, after which momentum began building. Consequently, it's likely the upper end of the guidance that we anticipate reaching. That's the way to look at it. Regarding instruments, what I mean is we keep observing considerable momentum there. At present, our guidance is 50 to 60 placements, yet a large number of our clinical customers keep growing their placements. So we remain convinced that substantial momentum opportunities exist here.

Ankur Dhingra

executive
#19

Mike, regarding the instrumentation piece, like I said during my prepared remarks, for Xs, indeed, roughly 200 to 240 across the year. On average, 50 to 60 each quarter remains pretty solid. Q4 placements were outstanding. We received a fair number of multipack orders. We're seeing a number of our customers looking to grow their fleets, at times considering scenarios involving tens of Xs. So instrument demand is healthy. As everyone is aware, we rolled out a significant software upgrade into X during 2025. Performance has been exceeding spec for a very substantial portion of our customer base. So X is delivering at an exceptionally high level; among our clinical customers, and research customers are incredibly enthusiastic about some of these emerging multiomic technologies that become enabled next; so very happy and quite strong thus far.

Kyle Mikson

analyst
#20

Hey, everyone. Appreciate you taking the questions. Nice work on a strong fourth quarter — particularly on the clinical side. With that in mind, I realize you don't break clinical out across the applications, but for a little context, it seems like oncology came in at slightly below $1.2 billion, and then genetic was a bit under $500 million. So which one of those do you think grows more quickly in '26? Just give us a hand in framing the various drivers and break it down a little further for us. And second, you mentioned some of the multiomics pieces earlier, maybe BioInsight. Does that move the needle this year? Thanks.

Jacob Thaysen

executive
#21

Yeah. Thanks, Kyle. Broadly speaking, we're obviously quite happy with clinical. And at the top level, clinical is expanding across every dimension — whether that's the various kinds of applications, or the various geographies and various customer types. So clinical delivered a really broad-based performance, and as we've said a handful of times here, we anticipate that carrying on. We continue to observe that oncology serves as the primary driver and the primary growth driver. Yet rare diseases are certainly expanding at a solid pace as well. So I do believe that across the coming year, oncology will likewise be the primary growth driver for us and for our customers.

Dan Arias

analyst
#22

Dan, thanks for those. Jacob here — I'd like to address how we're communicating with customers as we prepare for AGBT. You've consistently made the point that labs ought to concentrate on the complete workflow, and that viewed through that lens, opting for Illumina's offerings becomes the smarter play. So the real question is: at what point, and in what venue, should that play out visibly? Can you spell out for folks how combining Fluent, NovaSeq, and Dragon yields superior economics? Or is it left to each person to work out on their own? Since the logic sounds sound, yet I don't detect that buyers perceive it, nor that they can run the numbers and reach that same verdict. Should we anticipate a shift on that front?

Jacob Thaysen

executive
#23

Jacob: Yes, Dan. Honestly, that's precisely the dialogue we're having with our clientele. We're eager for the upcoming AGBT meeting in a few weeks, where — as I noted during prepared remarks — we hold the gold sponsorship, handing us a strong stage for ourselves as well as key opinion leaders to discuss how these various technologies get used and how to evaluate them, spanning top-tier quality insight through the most minimal end-to-end. Naturally, part of that involves demonstrating that this can be done at lower cost while still generating the strongest insight. It varies somewhat by assay. Take Constellation MAP Reads: there's essentially no hands-on work at the front end of the workflow, and you get lots of insight from very little workflow — minimal hands-on effort. That's a case where you begin removing library prep expenses while extracting far greater insight. It's a solid illustration of how to approach this, and you'd enjoy excellent pricing transparency from our side, since what remains is purely sequencing cost, whereas competitors must also handle library prep and additional steps. That's one instance, and we'll dive deeper at AGBT. The same logic now applies to Somalogic, the business we recently acquired, where we'll step forward and share cost per sample and cost per experiment — which I believe will prove another highly significant one. These discussions with customers are underway already, and we'll keep bringing all of you up to speed as well.

Jack Meehan

analyst
#24

Thanks. Afternoon, everyone. Hi, Jack. I'd like to follow up on what Dan asked. Let's stay on the AGBT topic. On the competition side, it appears that at least one rival has brought up a cost of $100 for each genome. I realize you're attempting to shift how that subject is framed, but I was wondering — when investors come across headlines like that, what does it imply for you? I don't know how your list pricing works, though obviously discounts apply. Could you explain what the effect on Illumina would be if headlines like that begin appearing?

Jacob Thaysen

executive
#25

Yes. We're eager for AGBT. Naturally, it's the conference where every one of our rivals will present their strongest offering. We'll do the same. As I said before, our customers consider far more than a single parameter or feature. They're too sophisticated to focus on just one element. So I believe you'll also see us emphasizing the aspects our customers are truly enthusiastic about, seen through the lens of the entire workflow. That said, I'd add that we believe we possess the portfolio, the pipeline, and the ability to compete across every parameter. So I'm quite confident about our position and our capabilities. Naturally, should chances arise to serve market segments at an alternate price point where elasticity is substantial, we've all pursued that, and we hold those discussions with our customers routinely. And we'll keep doing that.

Casey Woodring

analyst
#26

Hi there, and thanks for fielding my questions. First, you mentioned that you'd be re-examining your China projections while engaging with the authorities. Could you take us through how those discussions are progressing and what possible results might look like? Then for my second question, it's about BioInsight. Given all the attention AI is receiving right now, I was hoping you might expand on what you said earlier. I'm interested in how you intend to generate revenue from these offerings down the line, the degree of excitement you're hearing from pharmaceutical clients, and whether there's a method to put a number on the sales potential in the coming years. Thanks.

Jacob Thaysen

executive
#27

Yes, thank you, Casey. Regarding your first question about China, let me start by reminding everyone that this remains under 5% of our overall business. I'm genuinely happy with the efforts Jenny, our China general manager, and her team have made. They've managed to support our clients throughout the last year and are still doing so. As we've been keeping all of you informed recently, we've engaged in productive discussions and cooperation with Chinese regulatory authorities to make sure our operations there can keep going. However, we're still on the UAL. We're positive about the connection we have and our ability to navigate the process of bringing instruments in or out of China. Naturally, if you haven't been selling a particular instrument for an extended stretch, rebuilding that pipeline takes a while, and I believe that's largely what's behind what we're observing today. Yet, as Ankur pointed out, we do have a goal for China. If there's a path to being removed from that list, or some kind of improvement, I'd see potential for growth in the China business. Still, we're confident we have decent visibility at least through '26 as things stand. Turning to BioInsight, we're quite enthusiastic about what's possible there. It's still very early. When we introduced the Billion Cell Atlas at JPMorgan last year, the response was extremely positive. As I noted, we've had numerous discussions with pharmaceutical firms eager to tap into the Cell Atlas. It delivers profound insights for drug discovery, helping them select the best targets to pursue, so we definitely perceive growing interest in that area. As we said before, we're confident that this, alongside our multiomics operations, will begin generating at least 1% to 2% growth in '27. But you could view that as gaining speed right now. Ankur, perhaps you'd like to add something?

Ankur Dhingra

executive
#28

Right. Regarding BioInsight, there are a few additional points, as Jacob mentioned. Our aim with BioInsight, we believe, is to engage straight with our pharmaceutical clients and essentially bring in a third category of customers; and our perspective spans 5 years. That represents quite a substantial chance. The Billion Cell Atlas has gotten an excellent response, and enthusiasm following the conference has been enormous; thus we're quite happy with the initial moves we've made in this area. The approach to monetization would take 2 or 3 distinct forms. First involves highly tailored data and AI tool development; and eventually, we foresee considerable subscription-driven approaches through which we can assist pharma businesses on both the discovery and the development sides. However, that opportunity stretches across multiple years.

David Westenberg

analyst
#29

That was my fault. So now I'm audible to you, correct? Okay. Great. Yes. Great. Okay. Could you talk about what kind of discussions are happening with Academic Core Labs regarding spending on instruments? I'd assume they weren't the largest purchasers of instruments during 2025. What does your guidance assume for academia, both on consumables and on instruments? Also, you brought Eric Green aboard. So is there anything he can do to help spark some confidence in your academic business? I realize the NIH is up a little. Will they actually buy into that? And sorry. They'll add one more thing onto Jack and Dan's pricing versus competitors question. You're delivering significantly better specs, as I understand it, which translates into greater output; for many of your customers, that's a straightforward cost reduction when measured as cost per gigabase. Correct? So even when they get 25 gigabases for $200, they're in fact receiving less than that, since the output has been higher. I just want to check whether that assumption holds. Thank you.

Jacob Thaysen

executive
#30

Dave, thank you for your one question. I'll begin with the first one. Over the past eighteen months, I believe we've really expanded our relationship with the academic core labs, with a strong focus on making sure we can support them as well, of course, during a very difficult environment. So clearly they've faced challenges from the impact of NIH funding, of course, and other kinds of funding. Still, I think we've done a very good job — and this is also what they tell us — of supporting them both whenever they have chances to buy instruments. We've ensured we can place Xs in those kinds of labs as well, so they can capture every benefit the Xs offer. And I do believe that now, with Dr. Eric Green here, there are more chances to assist them and guide them through a challenging situation. As we've said, and as you noted, at least we now have improved line of sight to NIH funding, though some details still need to fall into place before we truly begin to see the various institutes and various core labs keep moving forward. You're correct that if you look at — and this is our — we have a tradition of going out and delivering on power beyond our specs. That's something we take pride in, and something our customers know about Illumina: we don't chew on and promise something we can't honor. We will in fact honor it and surpass it too. I think that's something many could learn from. So we'll keep doing that. Meanwhile, customers are reaping those benefits.

Subhalaxmi Nambi

analyst
#31

Hi, everyone. Thanks for letting me ask. It looks like that 6,000 pull-through is staying stronger than people thought. Going forward, has it stabilized, or does it remain a significant headwind? Then, on a separate note, plenty of attention has rightly gone to US clinical strength. Still, could you describe what growth might look like this year in Europe and Asia? And would you anticipate any differences versus the US market across this year? Thanks a lot.

Jacob Thaysen

executive
#32

Yes; so, Subbu, I'll begin with the 6Ks. What you're observing is something we've mentioned previously: a lot of our customers who are transitioning are either developing their new assays on the X platform, while retaining the NovaSeq 6K for their traditional assays that are already developed, that they've already validated, and they wish to keep; so that's also what you're seeing among customers who've chosen to remain with assays on the platform. They continue running those assays there, which is why pull-through keeps showing up. Naturally, some customers have moved off the 6Ks, and now they're shifting to the X, where they're experiencing considerable growth. So that explains why we see pull-through remaining elevated. Yet we still expect, naturally, that 6K customers will decline steadily over time.

Ankur Dhingra

executive
#33

Subbu, regarding the 6Ks and that shift — as you're aware, on the research side we've largely finished moving over, and clinical is now entering the later stage of that same transition. What we anticipate is that once we reach the close of 2026, the 6K transition ought to be mostly, substantially finished. On the volume front, it tracks the patterns we've been observing. So that's the way we're viewing it.

Jacob Thaysen

executive
#34

In terms of geography, Europe has performed extremely strongly. It has maintained quite healthy expansion across recent years, in my view, and we anticipate that trend carrying forward as we move into 2026. Additionally, we look for our APAC region, MER meeting, to recover to some degree.

Conor McNamara

executive
#35

We appreciate you being here with us today. A recording of this session can be found in the Investors area of our site. That brings our call to a close, and we hope to connect with you at events in the near future.

Operator

operator
#36

That wraps up the call for today. Thanks for joining us. At this point you're free to drop off, and we hope the rest of your day goes well.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Illumina, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Illumina, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Illumina, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.